A Randomized, Double-Blind, Parallel-Group, Active Controlled Trial With Open-Label Safety Extension to Evaluate the Tolerability, Safety, and Efficacy of Atogepant Versus Topiramate in Subjects Requiring Preventive Treatment of Migraine (TEMPLE)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 26 Nov 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Atogepant (Primary) ; Topiramate
Indications Migraine with aura; Migraine without aura
Focus Adverse reactions
Acronyms ATO-TOPIRAMATE; TEMPLE
Sponsors AbbVie

Most Recent Events

22 Nov 2024 Planned primary completion date changed from 20 May 2026 to 24 Apr 2025.
15 Nov 2024 Planned End Date changed from 28 Jun 2026 to 20 May 2026.
15 Nov 2024 Planned primary completion date changed from 14 Jun 2026 to 20 May 2026.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight